Don't Rush to Prescribe Olumiant or Xeljanz XR for Rheumatoid Arthritis

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second Janus kinase (JAK) inhibitor for RA on the market after Xeljanz.

And now once-daily Xeljanz XR may simplify dosing over Xeljanz BID.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote